Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isunakinra
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Buzzard Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : 3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.
Brand Name : EBI-005
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 07, 2021
Lead Product(s) : Isunakinra
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Buzzard Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VLPs based vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : SpyBiotech
Deal Size : Undisclosed
Deal Type : Agreement
3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement
Details : SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 27, 2020
Lead Product(s) : VLPs based vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : SpyBiotech
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : TOL2
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Toleranzia
Deal Size : Undisclosed
Deal Type : Partnership
3P Bio and Toleranzia Enter Orphan Drug Partnership
Details : Toleranzia’s innovative candidate (TOL2) is being developed for the treatment of the autoimmune neuromuscular disease Myasthenia Gravis (MG), an orphan disease, which has a major unmet medical need and a large market potential.
Brand Name : TOL2
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : TOL2
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Toleranzia
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?